Gilead Sciences, Inc. (NASDAQ:GILD) Stake Boosted by Trust Co. of Vermont
Trust Co. of Vermont raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,025 shares of the biopharmaceutical company’s stock after buying an additional 1,644 shares during the period. Trust Co. of Vermont’s holdings in Gilead Sciences were worth $2,990,000 as of its most recent filing with the SEC.
A number of other large investors have also made changes to their positions in the company. First Allied Advisory Services Inc. increased its stake in shares of Gilead Sciences by 0.5% in the fourth quarter. First Allied Advisory Services Inc. now owns 98,360 shares of the biopharmaceutical company’s stock valued at $7,044,000 after buying an additional 463 shares in the last quarter. Meridian Wealth Management LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at about $216,000. Cim Investment Mangement Inc. increased its stake in shares of Gilead Sciences by 1.1% in the fourth quarter. Cim Investment Mangement Inc. now owns 14,051 shares of the biopharmaceutical company’s stock valued at $1,006,000 after buying an additional 158 shares in the last quarter. Smith Shellnut Wilson LLC ADV acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at about $308,000. Finally, Bluestein R H & Co. increased its stake in shares of Gilead Sciences by 1.2% in the fourth quarter. Bluestein R H & Co. now owns 3,665 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 45 shares in the last quarter. 74.03% of the stock is owned by hedge funds and other institutional investors.
Shares of Gilead Sciences, Inc. (GILD) opened at 71.15 on Tuesday. The firm has a market cap of $92.97 billion, a price-to-earnings ratio of 7.52 and a beta of 1.20. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $88.85. The company has a 50-day moving average price of $66.03 and a 200 day moving average price of $68.95.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.18 by $0.02. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.66 billion. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. Analysts expect that Gilead Sciences, Inc. will post $8.37 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, June 29th. Investors of record on Friday, June 16th were given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date of this dividend was Wednesday, June 14th. Gilead Sciences’s dividend payout ratio is currently 21.99%.
Several brokerages recently issued reports on GILD. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price objective for the company in a research note on Monday, June 26th. J P Morgan Chase & Co reissued an “overweight” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 4th. Jefferies Group LLC reissued a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 4th. Cowen and Company reaffirmed an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a research note on Wednesday, July 5th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a research note on Thursday, July 13th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, fifteen have assigned a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $80.24.
In related news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares in the company, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold 88,276 shares of company stock worth $6,230,610 in the last three months. 1.30% of the stock is currently owned by company insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.